CSL Biotherapies announced today that it has signed a $180 million contract with the U.S. Department of Health and Human Services to provide Novel A, or H1N1, influenza vaccine antigen in bulk form to support the department's pandemic influenza preparedness efforts.
An antigen is a substance that stimulates an immune response.
CSL Biotherapies, a King of Prussia unit of Australia's CSL Limited, expects to deliver the first product by September.
The new vaccine antigen will be tested in clinical trials funded by HHS. - Miriam Hill